Sentiment for Bridgepoint Education Inc (BPI)
Bridgepoint Education Inc (BPI) investors sentiment decreased to 0.58 in Q2 2018. It’s down -0.28, from 0.86 in 2018Q1. The ratio has dropped, as 32 active investment managers started new and increased positions, while 55 sold and reduced stock positions in Bridgepoint Education Inc. The active investment managers in our database now own: 20.21 million shares, down from 21.59 million shares in 2018Q1. Also, the number of active investment managers holding Bridgepoint Education Inc in top ten positions was flat from 0 to 0 for the same number . Sold All: 24 Reduced: 31 Increased: 15 New Position: 17.
Since May 21, 2018, it had 0 insider buys, and 9 selling transactions for $10.24 million activity. 6,401 shares were sold by FOSTER JAMES C, worth $707,472 on Monday, May 21. $1.45M worth of Charles River Laboratories International, Inc. (NYSE:CRL) was sold by Molho Davide on Monday, July 23. $476,962 worth of Charles River Laboratories International, Inc. (NYSE:CRL) was sold by Girshick Birgit. $3.18 million worth of stock was sold by JOHST DAVID P on Wednesday, November 7. 300 shares were sold by MASSARO GEORGE, worth $34,665. On Tuesday, September 4 Kochevar Deborah Turner sold $502,799 worth of Charles River Laboratories International, Inc. (NYSE:CRL) or 4,066 shares.
Investors sentiment increased to 1.43 in Q2 2018. Its up 0.30, from 1.13 in 2018Q1. It improved, as 14 investors sold Charles River Laboratories International, Inc. shares while 92 reduced holdings. 45 funds opened positions while 107 raised stakes. 48.49 million shares or 9.51% more from 44.28 million shares in 2018Q1 were reported. Hartford Invest Mgmt owns 3,245 shares for 0.01% of their portfolio. Gemmer Asset Mngmt Ltd holds 0.01% or 156 shares in its portfolio. Cap Financial Advisers holds 9,861 shares or 0.01% of its portfolio. Aqr Capital Management Limited Liability Co reported 0.18% in Charles River Laboratories International, Inc. (NYSE:CRL). Qs Investors Ltd Liability Co stated it has 0.05% of its portfolio in Charles River Laboratories International, Inc. (NYSE:CRL). Riverhead Mngmt Ltd Liability Corp holds 3,474 shares. Renaissance Technology Limited Company holds 0.17% or 1.46M shares. Bbva Compass Savings Bank Inc accumulated 5,777 shares. Principal Financial Group Inc Incorporated stated it has 212,906 shares. California Public Employees Retirement System holds 100,871 shares. Schroder Inv Mgmt Gp, Maine-based fund reported 77,462 shares. Retirement Systems Of Alabama reported 145,241 shares. 5,950 were accumulated by First Quadrant L P Ca. Cornercap Invest Counsel holds 0.27% of its portfolio in Charles River Laboratories International, Inc. (NYSE:CRL) for 16,870 shares. State Of Tennessee Treasury Department has 0.01% invested in Charles River Laboratories International, Inc. (NYSE:CRL).
The stock increased 0.23% or $0.3 during the last trading session, reaching $130.88. About 460,884 shares traded or 16.62% up from the average. Charles River Laboratories International, Inc. (NYSE:CRL) has risen 18.17% since November 18, 2017 and is uptrending. It has outperformed by 2.55% the S&P500. Some Historical CRL News: 10/05/2018 – Charles River Labs 1Q Net $52.6M; 22/05/2018 – SIGNALFX SAYS $45 MLN IN SERIES D FUNDING LED BY GENERAL CATALYST WITH PARTICIPATION FROM ANDREESSEN HOROWITZ, CHARLES RIVER VENTURES; 24/05/2018 – RECRO: CRL RAISED CMC RELATED QUESTIONS ON EXTRACTABLE; 10/04/2018 – Charles River Laboratories Focuses on the Future of Oncology at AACR Annual Meeting 2018; 24/04/2018 – Charles River Short-Interest Ratio Rises 48% to 8 Days; 26/03/2018 – APRICUS BIOSCIENCES INC – INTEND TO FURTHER CLARIFY DEFICIENCIES RAISED IN CRL AND INFORMATION THAT MAY BE NEEDED TO RESOLVE SUCH DEFICIENCIE; 08/03/2018 – ACELRX PHARMACEUTICALS INC – ACELRX PROPOSED POTENTIAL RESOLUTIONS FOR TWO MAIN POINTS IDENTIFIED IN CRL RECEIVED FROM FDA IN OCTOBER 2017; 16/05/2018 – EVOLUS INC – IN CRL, DEFICIENCIES CITED BY FDA WERE ISOLATED TO ITEMS RELATED TO CHEMISTRY, MANUFACTURING, AND CONTROLS PROCESSES; 24/05/2018 – RECRO PHARMA INC – RECEIVED CRL FROM FDA REGARDING NEW DRUG APPLICATION FOR IV MELOXICAM; 09/05/2018 – LIPOCINE: CRL IDENTIFIED 4 DEFICIENCIES
Among 10 analysts covering Charles River (NYSE:CRL), 7 have Buy rating, 0 Sell and 3 Hold. Therefore 70% are positive. Charles River has $150 highest and $112 lowest target. $135’s average target is 3.15% above currents $130.88 stock price. Charles River had 14 analyst reports since June 15, 2018 according to SRatingsIntel. The rating was upgraded by RBC Capital Markets to “Outperform” on Tuesday, July 17. On Tuesday, September 11 the stock rating was maintained by Morgan Stanley with “Equal-Weight”. The company was maintained on Monday, September 17 by Robert W. Baird. The rating was maintained by Credit Suisse on Tuesday, September 25 with “Neutral”. Argus Research maintained Charles River Laboratories International, Inc. (NYSE:CRL) rating on Monday, August 27. Argus Research has “Buy” rating and $140 target. Robert W. Baird maintained Charles River Laboratories International, Inc. (NYSE:CRL) on Thursday, November 8 with “Outperform” rating. Jefferies maintained Charles River Laboratories International, Inc. (NYSE:CRL) rating on Thursday, August 9. Jefferies has “Buy” rating and $145 target. On Tuesday, August 21 the stock rating was maintained by Credit Suisse with “Neutral”. The stock has “Buy” rating by Bank of America on Monday, July 16. The firm earned “Overweight” rating on Friday, June 15 by KeyBanc Capital Markets.
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery and development services worldwide. The company has market cap of $6.30 billion. It operates through three divisions: Research Models and Services , Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). It has a 47.11 P/E ratio. The RMS segment produces and sells research model strains primarily genetically and microbiologically defined purpose-bred rats and mice for use by researchers.
The insider, and Charles River Laboratories International Inc’s Corporate Executive VP, David Johst, made a sale of 23,356 company shares on November 07, 2018, valued at $3,176,416 (at $136.0 per share). Having been a very huge insider stocks unloading at Charles River Laboratories International Inc, the probability that it stays disregarded for long was obviously very low. David Johst currently owns 196,493 shares which are equivalent to roughly 0.41% of the Massachusetts-Company’s market cap. The legal report was unveiled on November 07, 2018 with the D.C. based-SEC and is now available online here.
More news for Charles River Laboratories International, Inc. (NYSE:CRL) were recently published by: Seekingalpha.com, which released: “Charles River Laboratories beats by $0.15, beats on revenue” on November 07, 2018. Benzinga.com‘s article titled: “Earnings Scheduled For November 7, 2018” and published on November 07, 2018 is yet another important article.
The stock decreased 1.56% or $0.13 during the last trading session, reaching $8.19. About 97,594 shares traded. Bridgepoint Education, Inc. (BPI) has risen 15.78% since November 18, 2017 and is uptrending. It has outperformed by 0.16% the S&P500. Some Historical BPI News: 01/05/2018 – Bridgepoint Education 1Q Adj EPS 1c; 29/05/2018 – Bridgepoint bags a healthy return on Pret; 16/04/2018 – BRIDGEPOINT EDUCATION – JOSEPH D’AMICO, INTERIM CFO WILL CONTINUE WITH CO AS SPECIAL ASSISTANT TO CEO; 13/03/2018 – Ashford University and University of the Rockies Plan to Merge and Become an Independent, Non-profit University; 13/03/2018 – Bridgepoint Education Sees Transformations Completed by End 2018; 29/05/2018 – Bridgepoint unloads UK sandwich […]; 13/03/2018 – Bridgepoint Education, Inc. Plans to Separate from Ashford University, Improve Access to High-Quality Education; 13/03/2018 – Bridgepoint Education to Become an Online Program Management Company; 13/03/2018 – ASHFORD UNIVERSITY SAYS CO SUBMITTED APPLICATION TO WASC SENIOR COLLEGE AND UNIVERSITY COMMISSION TO MERGE WITH UNIVERSITY OF ROCKIES; 13/03/2018 – BRIDGEPOINT EDUCATION – PLANS TO SEPARATE FROM ITS ACADEMIC INSTITUTIONS, ASHFORD UNIVERSITY AND UNIVERSITY OF ROCKIES
Bridgepoint Education, Inc., together with its subsidiaries, provides postsecondary education services. The company has market cap of $222.30 million. The Company’s academic institutions, Ashford University and University of the Rockies, offer associate’s, bachelor’s, master’s, and doctoral degree programs in the disciplines of business, education, psychology, social sciences, and health sciences. It has a 12.39 P/E ratio. The firm offers its programs primarily through online; and at its campuses.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.